RNS Number : 2896W
Maven Income and Growth VCT 5 PLC
12 July 2024
 

Maven Income and Growth VCT 5 PLC

 

Interim Results for the Six Months Ended 31 May 2024 (Unaudited)

 

The Directors announce the Interim Review and the unaudited Financial Statements for the six months ended 31 May 2024.

 

Highlights

 

•    NAV total return at 31 May 2024 of 84.09p per share

 

•    NAV at 31 May 2024 of 32.09p per share

 

•    Interim dividend of 1.00p per share

 

•    Offer for Subscription closed, raising £6.8 million

 

•    Four new private companies added to the portfolio

 

•    Exit achieved from GradTouch, generating a total return of 1.7x cost

 

•    Post period end, final exit achieved from Quorum Cyber, generating a total return of 8.2x cost

 

Interim Review

 

Overview

 

In the six months to 31 May 2024, your Company has made further positive progress and it is pleasing to report a modest increase in NAV total return. Since the year end, your Company has closed its most recent Offer for Subscription, completed four new private company investments and achieved three profitable private company realisations, including the final exit from Quorum Cyber, which generated a total return of 8.2x cost over a holding period of less than four years. In general, the portfolio of investee companies continues to deliver a resilient performance and remains well placed to achieve further growth. In recognition of the exit activity and the commitment to make regular tax free distributions, an interim dividend of 1.00p per share has been declared for payment in September 2024.

 

Following a prolonged period of macroeconomic uncertainty, it is encouraging to note that market conditions are improving. With inflation significantly reduced, energy prices in decline and interest rates predicted to fall later in the year, the outlook is more stable than it has been for several years. Whilst it may take time for all of these improvements to filter through the economy, the Manager is cautiously optimistic in the outlook for the remainder of the financial year and believes that economic growth will continue to strengthen in 2025.

 

Your Company continues to make further progress in line with its long term growth strategy, which is focused on constructing a large and diverse portfolio of innovative companies that will scale and ultimately become attractive to a wide range of acquirers. During the reporting period, there was a good level of investment with the addition of four new private companies to the portfolio, alongside the provision of follow-on funding to support the further development of seven existing portfolio holdings, resulting in the deployment of £1.8 million. The investment strategy continues to focus on identifying entrepreneurial companies that operate in disruptive or high growth markets, where there is an opportunity to achieve scale over the medium term. Maven retains a strong preference for investing in companies that operate in dynamic sectors such as cyber security, software, niche manufacturing, data analytics, healthtech and training, where growth is less sensitive to consumer or discretionary spending and the revenue model tends to be recurring in nature, which provides good visibility on the growth trajectory of each portfolio company. To ensure the business plan can be delivered, Maven also spends time assessing the calibre of management and their track record, recognising that ambitious and cohesive teams are crucial to the success of early stage businesses.

 

In April 2024, your Company closed its most recent top-up Offer having raised a total of £6.8 million for the 2023/24 and 2024/25 tax years. These funds will enable your Company to progress its investment strategy which, over the past four years, has provided growth capital to more than 40 private companies, many of which are delivering strong growth and achieving a leading position in their respective markets. As the portfolio develops, it is becoming evident that there are a number of high performing companies which have the capability of achieving superior returns at exit.

 

Over recent months, there has been an increase in the level of acquisition interest across the portfolio with approaches to acquire or invest in several investee companies, particularly from US investors, who are interested in the UK technology sector. This is demonstrated by the recent successful exit from cyber security specialist Quorum Cyber, which completed in early June. Your Company first invested in Quorum Cyber in 2020, backing an experienced team that had quickly established a leading position in a high growth market. Following a period of rapid expansion, the investment was partially realised through a sale to UK private equity house Livingbridge in December 2021, generating an initial return of 6.5x cost over an 18 month holding period. This transaction provided Quorum Cyber with additional capital to support the next phase of its strategic development and, in recognition of its continuing potential, the Maven VCTs retained a minority equity interest in the business in order to participate in future growth. It is pleasing to report that in June this year, a final exit from this investment was achieved through a sale of the business to US private equity firm, Charlesbank Capital Partners, taking the total proceeds to 8.2x cost.

 

Whilst achieving profitable exits in pursuit of Shareholder returns remains a key priority, this has to be balanced against selling a business too early before its value has been fully optimised. In cases like Quorum Cyber, where a business is performing strongly and has the potential to become a large and valuable asset, the Manager will seek, where possible, to retain an economic interest when structuring an exit. This approach will allow your Company to generate an initial cash return from a secondary transaction or partial sale, to help support the dividend programme, whilst retaining an ongoing equity interest in the business, which offers the potential for a further return in the future.

 

Dividend Policy

 

The Board and the Manager recognise the importance of tax free distributions to Shareholders and will seek, as a guide, to pay an annual dividend that represents 5% of the NAV per share at the immediately preceding year end.

 

Decisions on distributions take into consideration a number of factors, including the realisation of capital gains, the adequacy of distributable reserves, the availability of surplus revenue and the VCT qualifying level, all of which are kept under close and regular review. As the portfolio continues to expand and a greater proportion of holdings are invested in younger companies with growth potential, the timing of distributions will be more closely linked to realisation activity, whilst also reflecting the Company's requirement to maintain its VCT qualifying level.

 

Interim Dividend

 

In respect of the year ending 30 November 2024, an interim dividend of 1.00p per share will be paid on 6 September 2024 to Shareholders who are on the register at 9 August 2024. Since the Company's launch, and after receipt of this interim dividend, a total of 53.00p per share will have been paid in tax free Shareholder distributions. It should be noted that payment of a dividend reduces the NAV of the Company by the total amount of the distribution.

 

Dividend Investment Scheme (DIS)

 

Your Company operates a DIS, through which Shareholders can, at any time, elect to have their dividend payments utilised to subscribe for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax relief applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances.

 

Shareholders can elect to participate in the DIS in respect of future dividends by completing a DIS mandate form and returning it to the Registrar (The City Partnership). In order for the DIS to apply to the 2024 interim dividend, the mandate form must be received before 23 August 2024, this being the relevant dividend election date. The mandate form, terms & conditions and full details of the scheme (including tax considerations) are available from the Company's webpages at: mavencp.com/migvct5. Election to participate in the DIS can also be made through the Registrar's online investor hub at: maven-cp.cityhub.uk.com/login.

 

If a Shareholder is in any doubt about the merits of participating in the DIS, or their own tax status, they should seek advice from a suitably qualified adviser.

 

Offer for Subscription

 

The most recent Offer for Subscription closed to new applications on 26 April 2024, with your Company raising a total of £6.8 million for the 2023/24 and 2024/25 tax years. All new shares in relation to this Offer have now been allotted with four allotments for the 2023/24 tax and one allotment for the 2024/25 tax year.

 

This additional liquidity will facilitate the further expansion and development of the portfolio in line with the investment strategy. The funds raised will also allow your Company to maintain its share buy-back policy, whilst also spreading costs over a wider asset base, with the objective of maintaining a competitive ongoing charges ratio for the benefit of all Shareholders.

 

As announced on 18 June 2024, the Directors have elected to launch a new Offer for Subscription, which will run alongside Offers by the other Maven managed VCTs. Full details will be included in the Prospectus, which is expected to be published in Autumn 2024.

 

Portfolio Developments

 

It is encouraging to report on the progress that has been achieved across the private equity portfolio, where most companies have continued to meet operational and financial targets as part of their business plans. Notably, many of the earlier stage growth companies are now achieving scale and establishing strong positions in their respective markets, and in recognition of the progress achieved the valuations of certain holdings have been uplifted.

 

Carbon reduction software specialist Manufacture 2030 has delivered strong revenue growth over the past year, with annual recurring revenue (ARR) increasing by over 75%. The business provides a disruptive software solution that helps multinationals achieve Scope 3 carbon reduction targets by measuring, managing and reducing carbon emissions across their supply chain. The business is establishing a strong position in a high growth market, where its proposition is aligned with various carbon reduction initiatives, including the United Nations Sustainable Development Goals. Manufacture 2030 partners with a wide range of blue chip clients including Asda, Co-op, GSK, Toyota and Unilever, and has received a number of awards as a technology pioneer within this evolving market. The near term objective is to expand its presence in North America, which is viewed as a key market.

 

Specialist electronics manufacturer CB Technology delivered a positive performance in its latest financial year and continues to build a strong forward orderbook, which provides good visibility for the year ahead. CB Technology has also secured a number of new clients as part of a successful diversification strategy, with the objective of reducing the reliance on oil & gas customers.

 

Cyber security specialist CYSIAM has made further commercial progress with revenues increasing by more than 200% since your Company first invested. The business is building a strong reputation as a leading provider of Managed Detection and Response (MDR) security services for protection against, detection of, and response to cyber attacks. CYSIAM is a recognised expert in its field and, as an accredited member of the National Cyber Security Centre's Cyber Incident Response scheme, it can provide direct support to a range of organisations when they become victims of cyber attacks. CYSIAM operates in a dynamic, high growth market and the near term strategic objective remains to further pivot the business towards a Software as a Service (SaaS) model, which will result in an increased level of recurring revenue.

 

In 2021, your Company invested in Guru Systems a supplier of hardware, software and data analytics designed to improve the performance and cost effectiveness of heat networks. Since investment, the business has gained commercial traction in an emerging sector that has positive ESG credentials. Heat networks are an important part of the government's decarbonisation strategy and are increasingly required to be included as part of the design of any new residential and commercial property developments. Given the strong growth potential of this market, Guru is well placed to achieve scale over the medium term.

 

During the period under review, digital archiving specialist MirrorWeb has continued to deliver impressive revenue growth and add new clients. Following the relocation of the CEO to the US to lead the international expansion strategy, the business has continued to scale rapidly, particularly in the financial services sector, where regulatory changes now require all digital communications to be archived. MirrorWeb has also focused on developing a new platform with enhancements and additional product functionality, which provides good upselling potential within the existing client base.

 

Automotive ecommerce software specialist Rockar continues to grow market share and is now a leading provider of a white label disruptive solution for buying and selling new and used cars online. The business has developed good relationships with various high profile automotive manufacturers such as BMW, Jaguar Land Rover, Toyota Motor Group and Volvo UK, with development work ongoing with several others. Rockar's new operating platform, Evolution, is gaining traction amongst clients, with a number already using or committed to migrating across to the new operating system. The business continues to deliver strong revenue growth and remains focused on building relationships with global automotive manufacturers that will enable the company to achieve further scale.

 

Digital payments software provider QikServe has continued to make encouraging commercial progress and is capitalising on the shift within the hospitality sector towards mobile ordering and pay-at-table technology. The business continues to expand its market presence in targeted sectors, which include restaurants, international coffee chains and transportation hubs. QikServe has a growing estate with more than 8,000 sites in over 40 countries and a healthy pipeline of near term opportunities, particularly in the US.

 

Contract software specialist Summize continues to make positive commercial progress, with ARR growing by almost 200% since the investment first completed in October 2022. Summize has developed an AI-powered digital contracting software solution that simplifies and streamlines the process for writing and renewing contracts, helping to drive operational efficiencies for customers. Since inception in 2018, Summize has secured numerous industry awards for its innovation and entrepreneurialism. Having established a strong foothold in the UK, the next phase of growth for the business is to expand into the US, where it has the potential to exploit a significant market opportunity.

 

As may be expected with a large portfolio, there are a small number of investee companies that have not achieved commercial targets and are trading behind plan. Protective provisions have, therefore, been taken against the cost of certain holdings.

 

The performance of fintech specialist Delio has been impacted by slower than expected sales cycles and although corrective measures have been taken, the business continues to trade behind plan. It is disappointing to report that the small investment in marketing technology business Drovo has been written down in full.

 

Quoted Holdings

 

Following a challenging year for markets in 2023, there are signs that AIM has stabilised, with the FTSE AIM All-Share Index increasing by 12.9% over the period under review, and your Company's AIM quoted portfolio rising by 7.7%. The Manager continues to review a wider range of AIM investment proposals but will maintain a highly selective approach to supporting any new investment opportunities.

 

Concurrent Technologies, the designer and manufacturer of high performance embedded computing solutions, delivered record revenues and profitability in the full year to 31 December 2023. Annual revenue grew by 73% to £31.7 million, driven by robust demand from defence customers, which account for 85% of total revenue, with profit before tax (PBT) increasing to £3.7 million. The cash position at the end of the year was £11.1 million, of which £5.6 million was generated from operating activities. Concurrent has maintained this positive momentum into the new financial year with trading in the first four months of the year in line in market expectations.

 

Predictive health technology specialist GENinCode, which focuses on genetic risk assessments of cardiovascular disease and ovarian cancer, published encouraging results for the full year to 31 December 2023. During the year, revenue increased by 51% to £2.2 million, driven by increased usage of its tests in the UK and Europe. The business also commenced commercial programmes in the US for its cardiovascular disease genetic risk assessments and filed for Food and Drug Administration (FDA) approval of the CARDIO inCode device, a polygenic risk assessment of coronary heart disease. In January 2024, your Company participated in a small follow-on fundraise to support the business through the approval timeline to the point of the first commercial sale of LIPID inCode, a genetic diagnosis and risk assessment of familial hypercholesterolemia.

 

In the first half of the year to 31 December 2023, customer engagement software specialist Netcall reported revenue growth of 8% to £18.9 million, driven by growth in cloud services, with recurring revenue increasing to 75% of total revenue. PBT was 61% higher at £3.8 million, with the cash position at the period end increasing to £28.6 million. The business has seen ongoing positive momentum into the second half of the year, as it continues to benefit from favourable market conditions, including the rapid acceleration of cloud and AI technologies.

 

Security and surveillance specialist Synectics reported good growth in the year to 30 November 2023 driven by strong demand from the oil & gas sector. Revenue rose by 26% to £49.1 million, with underlying PBT up 190% to £2.9 million. There was strong cash generation from operating activities, and, at the year end, the cash position was £4.6 million, with the final dividend increased by 50% to 3p per share. This positive momentum had continued into the new financial year, and trading remains comfortably in line with market expectations.

 

Water Intelligence, a provider of minimally invasive leak detection and remediation solutions, released an encouraging trading update for the year to 31 December 2023. During the period, revenue increased by 7% to $76 million, with adjusted PBT increasing by 12% to $8.7 million. This was followed by a similarly positive quarterly trading update for the period to 31 March 2024, which stated that revenue was 6% ahead at $20.5 million, with adjusted PBT growing 8% to $2.5 million. Post the quarter end, the company announced another franchise reacquisition and a new franchise arrangement, both of which are expected to provide positive momentum going forward.

 

Treasury Management

 

Your Company maintains a proactive approach to treasury management, where the objective remains to optimise the income generated from cash held prior to investment in VCT qualifying companies, whilst meeting the requirements of the Nature of Income condition. This is a mandatory part of the VCT legislation, which stipulates that not less than 70% of a VCT's income must be derived from shares or securities. During 2023, the rise in interest rates required the Board and the Manager to revise its approach and, following a whole of market review, the composition of the treasury management portfolio was expanded to include holdings in leading money market funds and open-ended investment companies (OEICs), alongside carefully selected London Stock Exchange listed investment trusts. This approach enables your Company to maintain compliance with the Nature of Income condition, whilst also generating a healthy new stream of income from the portfolio of treasury management holdings and cash.

 

In line with the liquidity requirements of your Company, there were several new investments and realisations within this portfolio, details of which can be found in the Interim Report.

 

New Investments

 

During the reporting period, four new private companies were added to the portfolio:

 

•    Alderley Lighthouse Labs is a provider of clinical diagnostic testing services, specialising in the analysis of human samples such as blood, urine and cells, with the objective of improving healthcare outcomes. The business was initially established as a COVID-19 testing facility, as part of the Government supported "Test and Trace" programme. As pandemic related testing subsided, the business evolved into a laboratory-based facility providing blood science and molecular diagnostics to a wide range of clients. The healthcare diagnostics and testing market continues to experience high growth, and Alderley is well placed to leverage its existing position, with scope to achieve considerable scale. The funding from the Maven VCTs provides capital that will enable the business to invest in product development, expand its current suite of services and grow monthly revenues.

 

•    McKenzie Intelligence Services (MIS) is an insurtech business that provides insurers with geospatial data and analysis to accelerate responses to catastrophic events, helping to drive disaster relief and economic recovery. Its proprietary data-led intelligence platform, Global Events Observer, uses real time information, machine learning and expert analysis to provide detailed and actionable intelligence to help decision makers manage risk, escalate relief and promote economic recovery in scenarios of extreme weather, natural disasters and geopolitical conflict. Since 2017, MIS has been Lloyds of London's catastrophic claims partner and has provided data and assistance following several high profile incidents, including the 2023 wildfires in Hawaii. The funding from the Maven VCTs is being used to further develop the technology platform and to launch new products that offer unique insight into future potential risks.

 

•    Metrion Biosciences is a specialist contract research organisation that provides drug discovery services to pharma and biotech customers. Its highly specialised service is required in the development of drugs that intentionally or unintentionally act on an important group of protein structures within the body known as ion channels, which are one of the fastest growing areas of innovation in drug discovery. Metrion is aiming to become the outsourcing partner of choice for ion channel services in the global pharma and biotech industry. The funding from the Maven VCTs is being used to invest in new equipment and to create additional laboratory space, which will enable Metrion to achieve greater scale in this growing market.

 

•    Zing is a specialist services provider operating in the cloud-communications sector. It is a leading partner of global cloud communication platform business, Twilio, providing consultancy and managed services. Zing was a spin out from CRM provider ProspectSoft, a previous Maven portfolio company, which was successfully exited in 2022. The funding from the Maven VCTs will enable the business to capitalise on the growth opportunities in the Communications Platform as a Service (CPaaS) market. Since becoming an independent business, Zing has made encouraging commercial progress and strengthened its relationship with Twilio. The next stage of development is focused on expanding into the US, developing a new AI proposition, and enhancing the management team through new strategic hires.

 

The following investments were completed during the reporting period:

 

Investments

Date

Sector

£'000

 

New unlisted

 

 

 

 

Alderley Lighthouse Labs Limited1

April & May 2024

Pharmaceuticals,

biotechnology & healthcare

248

 

McKenzie Intelligence Services Limited

December 2023

Business services

159

 

Metrion Biosciences Limited

December 2023

Pharmaceuticals,

biotechnology & healthcare

597

 

Zing TopCo Limited (trading as Zing)1

April & May 2024

Business services

185

 

Total new unlisted

 

 

1,189

 

 

Follow-on unlisted

 

 

 

 

Hublsoft Group Limited

April 2024

Software & technology

56

 

Liftango Group Limited

March 2024

Software & technology

48

 

Relative Insight Limited

February 2024

Software & technology

99

 

Snappy Shopper Limited

April 2024

Software & technology

9

 

Whiterock Group Limited

December 2024

Software & technology

199

 

Zinc Digital Business Solutions Limited

May 2024

Software & technology

50

 

Total follow-on unlisted

 

 

461

 

 

 

 

 

 

Total unlisted

 

 

1,650

 

 

Follow-on AIM quoted

 

 

 

 

GENinCode PLC

January 2024

Pharmaceuticals,

biotechnology & healthcare

160

 

Total follow-on AIM quoted

 

 

160

 

 

Open-ended investment companies2

 

 

 

Royal London Short Term Money Market Fund (Class Y Income)

April 2024

Money market fund

1,000

Total open-ended investment companies

 

 

1,000

 

Money market funds2

 

 

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

March 2024

Money market fund

500

Fidelity Institutional Liquidity Sterling Fund (Class F)

March 2024

Money market fund

1,000

HSBC Sterling Liquidity Fund (Class A)

May 2024

Money market fund

1,000

Total money market funds

 

 

2,500

 

Private equity investment trusts2

 

 

 

Caledonia Investments PLC

May 2024

Investment trust

111

CT Private Equity Trust PLC

May 2024

Investment trust

300

ICG Enterprise Trust PLC

May 2024

Investment trust

51

Pantheon International PLC

May 2024

Investment trust

129

Total private equity investment trusts

 

 

591

 

Infrastructure investment trusts2

 

 

 

BBGI Global Infrastructure SA

May 2024

Investment trust

52

Pantheon Infrastructure PLC

May 2024

Investment trust

13

Total infrastructure investment trusts

 

 

65

 

 

 

 

Total investments

 

 

5,966

 

1 Follow-on investment completed in two tranches.

2 Investments completed as part of the treasury management strategy.

 

At the period end, the portfolio comprised of 137 unlisted and quoted investments, at a total cost of £62.2 million.

 

Realisations

 

In December 2023, the exit from Glacier Energy Services completed, through a sale to a private equity buyer, which generated a total return of 1.05x cost over the life of the investment. Glacier was one of the more mature holdings in the portfolio and the exit helps further reduce your Company's exposure to the energy services sector.

 

In May 2024, the exit from graduate recruitment specialist GradTouch completed. Your Company first invested in GradTouch in November 2019, backing a team with a strategic plan to build a market leading position in the graduate recruitment market. Throughout the period of ownership, the company achieved steady organic growth alongside completing a series of self funded, complementary acquisitions, which helped transform the business. During the period under review, an offer to acquire the business was received from UK private equity house Pelican Capital, which generated a total return of 1.7x cost, inclusive of a small deferred consideration.

 

The table below gives details of the realisations completed during the reporting period:

 

 

Realisations

Year first

invested

Complete/

partial exit

Cost of shares disposed

of

£'000

Value at 30 November

2023

£'000

 

 

Sales

proceeds

£'000

 

 

Realised

gain/(loss)

£'000

Gain/(loss) over 30 November

2023 value

£'000

Unlisted

 

 

 

 

 

 

 

Glacier Energy Services Holdings Limited

2011

Complete

643

509

486

(157)

(23)

GradTouch Limited

2019

Complete

566

955

973

407

18

Others

 

 

-

-

6

6

6

Total unlisted

 

 

1,209

1,464

1,465

256

1

 

AIM quoted

 

 

 

 

 

 

 

Oncimmune Holdings PLC

2021

Complete

249

35

33

(216)

(2)

SulNOx PLC

2021

Partial

130

113

153

23

40

Velocys PLC

2021

Complete

148

4

5

(143)

1

Verici Dx PLC

2020

Partial

7

3

3

(4)

-

Vertu Motors PLC

2007

Complete

50

71

59

9

(12)

Total AIM quoted

 

 

584

226

253

(331)

27

 

Money market funds1

 

 

 

 

 

 

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

2023

Partial

1,000

1,000

1,000

-

-

Goldman Sachs Sterling Government Liquid Reserves Ireland (Institutional)

2023

Complete

1,000

1,000

1,000

-

-

HSBC Sterling Liquidity Fund (Class A)

2023

Partial

1,000

1,000

1,000

-

-

Total money market funds

 

 

3,000

3,000

3,000

-

-

 

Open-ended investment companies1

 

 

 

 

 

 

 

Royal London Short Term Money Market Fund (Class Y Income)

2023

Partial

986

978

974

(12)

(4)

Total open-ended investment companies

 

 

986

978

974

(12)

(4)

 

 

 

 

 

 

 

 

Total sales

 

 

5,779

5,668

5,692

(87)

24

 

1 Realisations were completed as part of the treasury management strategy.

 

During the year, one private company was struck off the Register of Companies, resulting in a total realised loss of £100,000 (cost £100,000). This had no effect on the NAV of the Company as a full provision had been taken against the value of the holding in a previous period.

 

Principal and Emerging Risks and Uncertainties

 

The principal and emerging risks and uncertainties facing the Company were set out in full in the Strategic Report contained within the 2023 Annual Report, and are the risks associated with investment in small and medium sized unlisted and AIM/AQSE quoted companies which, by their nature, carry a higher level of risk and are subject to lower liquidity than investments in larger quoted companies. The valuation of investee companies may be affected by economic conditions, the credit environment and other risks including legislation, regulation, adherence to VCT qualifying rules and the effectiveness of the internal controls operated by the Company and the Manager. These risks and procedures are reviewed regularly by the Risk Committee and reported to your Board. The Board continues to monitor the criteria for VCT qualifying status and can confirm that these are being adhered to.

 

Global conflict and political instability was added to the Risk Register as an emerging risk during a previous period, as the Directors were not only aware of the heightened cyber security risk but were mindful of the impact that any change in the underlying economic conditions could have on the valuation of investment companies. These included fluctuating interest rates, increased fuel and energy costs, and the availability of bank finance, all of which could be impacted during times of geopolitical uncertainty and volatile markets. The Board and the Manager continue to monitor the impact of geopolitical issues, and wider market conditions, on portfolio companies.

 

Share Buy-backs

 

In order to maintain an orderly market in the Company's shares, the Directors have delegated authority to the Manager to enable the Company to buy back shares in the secondary market for cancellation or to be held in treasury, subject always to such transactions being in the best interests of Shareholders.

 

It is intended that the Company will seek to buy back shares with a view to maintaining a share price that is at a discount of approximately 5% to the latest published NAV per share, subject to market conditions, availability liquidity and the maintenance of the Company's VCT qualifying status. During the period under review, 5,663,662 shares were bought back at a total cost of £1.73 million.

 

Shareholders should note that neither the Company nor the Manager can execute a transaction in the Company's shares and an instruction to buy or sell shares on the secondary market must be directed through a stockbroker. If a Shareholder wishes to discuss a transaction, they or their broker can contact the Company's stockbroker, Shore Capital Stockbrokers on 020 7647 8132. Such transactions are, however, prohibited whilst the Company is in a closed period, which is the time from the end of a reporting period until the announcement of the relevant results, or the release of an unaudited NAV. Additionally, a closed period may be introduced if the Directors and Manager are in possession of price sensitive information.

 

VCT Regulatory Update

 

During the period under review, there were no further amendments to the rules governing VCTs, and your Company remains fully compliant with the complex conditions and requirements as set out by HMRC.

 

Although the precise details of the new government's economic and fiscal policy are currently unknown, the Manager has, through the VCT Association (VCTA), been actively involved in positive cross party dialogue to promote and reinforce the important role that VCTs play in supporting some of Britain's brightest and most entrepreneurial smaller companies, whilst also assisting in job creation across the regions. The announcement in the 2023 Autumn Statement that the "sunset clause" for VCT and EIS schemes would be extended until 2035 helps to ensure that VCTs remain an important component of the UK's funding infrastructure.

 

Valuation Methodology

 

Consistent with industry best practice, the Board and the Manager continue to apply the International Private Equity and Venture Capital Valuation (IPEV) Guidelines as the central methodology for all private company valuations. The IPEV Guidelines are the prevailing framework for fair value assessment in the private equity and venture capital industry. The Directors and the Manager continue to follow industry guidelines and adhere to the IPEV Guidelines in all private company valuations. In accordance with normal market practice, investments quoted on AIM, or another recognised stock exchange, are valued at their closing bid price at the period end.

 

Environmental, Social and Governance (ESG)

 

Whilst the Manager continues to enhance its ESG framework, it should be noted that your Company's investment policy does not incorporate specific ESG aims, and portfolio companies are not required to meet any specific targets. However, as a growth investor, Maven is well positioned to help each company establish robust ESG practices at an early stage of its corporate development, ensuring that they are ingrained in the culture as the business grows. The Manager believes that strong core ESG credentials helps support responsible growth and encourage positive social and environmental behaviours.

 

Your Company has multiple investments in companies with strong ESG credentials that are achieving growth in expanding markets. The Manager is committed to maintaining a responsible approach to new and existing investments and has developed a framework for promoting ESG credentials by actively engaging with portfolio companies, taking into consideration material issues at the point of investment as well as monitoring progress annually. All potential investment opportunities are required to complete an ESG assessment, which covers 10 key areas and provides a comprehensive pre-investment evaluation of the business with a focus on governance, board composition and culture, alongside environmental and social considerations.

 

The Manager continues to be an active signatory to the UN Principles for Responsible Investment (UNPRI) and Investing in Women Code. Alongside these external initiatives, Maven has developed internal diversity initiatives, including launching a Female Founder Funding programme, which aims to offer mentorship and collaboration opportunities to female entrepreneurs across the UK.

 

Outlook

 

With a small number of exceptions, the underlying portfolio of investee companies has delivered a resilient performance over the past few years and is well positioned to achieve further growth. Whilst 2023 was a slow year for exits across the private equity industry, there is clear evidence that M&A activity is improving. In addition to the three profitable private company exits completed in the year to date, the companies within the unlisted portfolio continue to attract regular acquisition interest from a wide range of credible UK and international acquirers. The completion of further profitable exits remains a key objective and will continue to be a focus of attention in the second half of the year, to help support your Company's dividend programme.

 

 

Graham Miller

Chair

 

12 July 2024

 

 

Summary of Investment Changes

 

For the Six Months Ended 31 May 2024

 

 

Valuation

30 November 2023

Net

Investment/

(disinvestment)

Appreciation/

(depreciation)

Valuation

31 May 2024

Portfolio

£'000

%

£'000

£'000

£'000

%

Unlisted investments

 

 

 

 

 

Equities           

37,095

58.5

1,007

849

38,951

57.4

Loan stocks

6,803

10.7

(822)

132

6,113

9.0

 

43,898

69.2

185

981

45,064

66.4

AIM/AQSE investments1

 

 

 

 

 

 

Equities           

4,544

7.1

(93)

362

4,813

7.1

 

Listed investments2

 

 

 

 

 

 

OEICs

2,027

3

26

(25)

2,028

3.0

MMFs

5,500

9

(500)

-

5,000

7.4

Investment trusts

3,767

5.9

656

259

4,682

6.9

Total portfolio

59,736

94.1

274

1,577

61,587

90.8

Cash

3,492

5.5

2,364

-

5,856

8.6

Other assets

332

0.4

63

-

395

0.6

Net assets

63,560

100.0

2,701

1,577

67,838

100.0

 

Ordinary Shares in issue

                                 

195,399,711

 

 

 

211,399,652

 

Net asset value (NAV) per Ordinary Share

                        32.53p

 

 

32.09p

 

Mid-market price

                        31.60p

 

 

30.40p

 

Discount to NAV

                         2.89%

 

 

5.27%

 

 

1               Shares traded on the Alternative Investment Market (AIM), the Aquis Stock Exchange (AQSE) and the Main Market of the London Stock Exchange.

2               These holdings represent the treasury management portfolio, which has been constructed from a range of carefully selected, permitted non-qualifying holdings in investment trusts, open-ended investment companies (OEICs) and Money Market Funds (MMFs).

 

 

Investment Portfolio Summary

 

As at 31 May 2024

 

Investment

Valuation

£'000

Cost

£'000

% of

total assets

% of

equity held

% of equity

held by

other clients1

Unlisted

 

 

 

 

 

MirrorWeb Limited

3,632

1,300

5.3

8.7

41.1

Bright Network (UK) Limited

2,493

1,264

3.6

7.2

31.9

Rockar 2016 Limited

(trading as Rockar)

1,683

1,023

2.4

4.7

14.8

2 degrees Limited

(trading as Manufacture 2030)

1,385

997

2.0

3.5

7.6

Horizon Technologies Consultants Limited

1,328

1,296

1.9

5.5

11.7

Horizon Ceremonies Limited

(trading as Horizon Cremation)

1,298

660

1.9

3.6

49.1

Summize Limited

1,222

647

1.8

4.1

28.3

Liftango Group Limited

1,195

1,195

1.8

8.2

32.5

Bud Systems Limited

1,057

846

1.6

4.7

13.0

DiffusionData Limited

1,006

725

1.5

3.5

14.5

Precursive Limited

1,000

1,000

1.5

6.8

27.7

Zinc Digital Business Solutions Limited

989

677

1.5

9.0

34.7

CYSIAM Limited

986

373

1.4

6.0

21.7

CB Technology Group Limited

979

521

1.4

10.1

64.9

NorthRow Limited

979

979

1.4

5.0

27.8

Hublsoft Group Limited

969

786

1.4

5.5

18.3

Nano Interactive Group Limited

929

625

1.4

3.7

11.2

Relative Insight Limited

899

899

1.3

5.0

26.3

Enpal Limited

(trading as Guru Systems)

891

891

1.3

7.5

14.1

mypura.com Group Limited

(trading as Pura)

862

448

1.3

2.1

20.8

Novatus Global Limited

861

861

1.3

5.4

13.4

Draper & Dash Limited

(trading as RwHealth)

860

860

1.3

7.7

41.2

iAM Compliant Limited

806

489

1.2

6.3

42.8

BioAscent Discovery Limited

785

174

1.2

4.4

35.6

Filtered Technologies Limited

785

750

1.2

4.1

21.3

ORCHA Health Limited

775

775

1.1

2.7

5.1

Whiterock Group Limited

729

520

1.1

9.3

28.6

Biorelate Limited

718

597

1.1

3.4

22.3

CODILINK UK Limited

(trading as Coniq)

675

450

1.0

1.3

3.6

Plyable Limited

647

647

1.0

7.3

19.3

Reed Thermoformed Packaging Limited (trading as iPac Packaging Innovations)

631

448

0.9

2.5

9.9

Turnkey Group (UK) Holdings Limited

604

1,208

0.9

15.6

23.1

QikServe Limited

602

494

0.9

2.2

13.6

Metrion Biosciences Limited

597

597

0.9

4.3

13.9

Sensoteq Limited

597

597

0.9

5.6

18.0

Ensco 969 Limited

(trading as DPP)

551

435

0.8

2.2

32.3

HCS Control Systems Group Limited

550

373

0.8

3.0

33.5

WaterBear Education Limited

506

245

0.7

5.0

33.8

Laverock Therapeutics Limited

498

498

0.7

2.3

7.0

Boomerang Commerce IQ Inc

(trading as CommerceIQ)2

484

646

0.7

0.1

0.3

HiveHR Limited

413

413

0.6

6.0

38.6

Vodat Communications Group (VCG) Holding Limited

396

264

0.6

2.3

29.6

Rico Developments Limited

(trading as Adimo)

380

760

0.6

3.4

6.5

Delio Limited

378

998

0.6

3.8

14.6

Project Falcon Topco Limited

(trading as Quorum Cyber)3

377

126

0.6

0.3

2.6

Flow UK Holdings Limited

350

498

0.5

6.0

29.0

Shortbite Limited

(trading as Fixtuur)

327

684

0.5

10.4

60.5

Servoca PLC4

322

136

0.5

1.2

-

Snappy Shopper Limited

307

307

0.5

0.4

1.3

ebb3 Limited

303

206

0.4

6.6

72.3

XR Games Limited

301

299

0.4

1.6

21.6

RevLifter Limited

300

300

0.4

3.1

23.5

Growth Capital Ventures Limited

275

264

0.4

4.8

42.6

AMufacture Limited

261

261

0.4

4.8

15.2

Alderley Lighthouse Labs Limited

249

249

0.4

6.7

46.9

Cat Tech International Limited

243

299

0.4

2.9

27.2

Automated Analytics Limited

220

150

0.3

1.9

18.7

The Algorithm People Limited

(trading as Optimize)

186

140

0.3

2.0

14.2

Zing TopCo Limited

(trading as Zing)

185

185

0.3

4.9

42.8

McKenzie Intelligence Services Limited

159

159

0.2

1.6

4.8

ISN Solutions Group Limited

65

250

0.1

3.6

51.4

Other unlisted investments

24

3,296

-

 

 

Total unlisted

45,064

39,060

66.4

 

 

 

AIM/AQSE quoted5

 

 

 

 

 

Water Intelligence PLC

905

163

1.4

1.2

-

Concurrent Technologies PLC

492

161

0.8

0.6

-

GENinCode PLC

368

557

0.6

4.5

17.2

Vianet Group PLC

355

405

0.5

1.1

0.3

Avingtrans PLC

350

54

0.5

0.3

-

Pulsar Group PLC

(formerly Access Intelligence PLC)

347

224

0.5

0.4

0.1

Netcall PLC

293

26

0.4

0.2

-

Synectics PLC

247

308

0.4

0.8

-

K3 Business Technology Group PLC

195

238

0.3

0.5

-

Kanabo Group PLC6

194

1,639

0.3

2.0

7.9

Anpario PLC

136

57

0.2

0.2

-

Eden Research PLC

133

199

0.2

0.6

0.9

Arecor Therapeutics PLC

115

167

0.2

0.2

0.2

Croma Security Solutions Group PLC

111

433

0.2

1.1

-

Intelligent Ultrasound Group PLC

98

118

0.1

0.4

1.5

BiVictriX Therapeutics PLC

83

99

0.1

0.9

-

Incanthera PLC

70

49

0.1

0.6

0.6

Transense Technologies PLC

44

1,188

0.1

0.3

-

Merit Group PLC

36

450

0.1

0.2

-

Feedback PLC

35

74

0.1

0.4

1.3

C4X Discovery Holdings PLC

28

40

-

0.1

0.8

Crossword Cybersecurity PLC

23

150

-

0.6

1.5

Avacta Group PLC

18

7

-

-

0.1

Verici Dx PLC

17

76

-

0.1

1.2

Destiny Pharma PLC

16

69

-

0.1

0.5

Directa Plus PLC

16

120

-

0.1

0.1

Gelion PLC

15

121

-

0.1

0.1

XP Factory PLC           

15

26

-

-

0.1

LungLife AI

12

114

-

0.3

0.2

Other quoted investments

46

4,283

-

 

 

Total AIM/AQSE quoted

4,813

11,615

7.1

 

 

 

Private equity investment trusts7

 

 

 

 

 

HgCapital Trust PLC

706

499

1.0

-

0.1

Patria Private Equity Trust PLC

(formerly abrdn Private Equity Opportunities Trust)

486

377

0.7

0.1

0.2

NB Private Equity Partners Limited

400

412

0.6

0.1

0.2

ICG Enterprise Trust PLC

329

305

0.5

-

0.2

CT Private Equity Trust PLC

297

300

0.4

0.1

0.3

Apax Global Alpha Limited

206

225

0.3

-

0.1

Pantheon International PLC

126

129

0.2

-

-

Caledonia Investments PLC

112

112

0.2

-

-

Total private equity investment trusts

2,662

2,359

3.9

 

 

 

Global equity investment trusts7

 

 

 

 

 

Alliance Trust PLC

181

149

0.3

-

-

JPMorgan Global Growth & Income PLC

175

150

0.3

-

-

Total global equity investment trusts

356

299

0.6

 

 

 

Real estate investment trust7

 

 

 

 

 

Impact Healthcare REIT PLC

220

244

0.3

0.1

0.1

Total real estate investment trust

220

244

0.3

 

 

 

Infrastructure investment trusts7

 

 

 

 

 

BBGI Global Infrastructure SA

336

372

0.5

-

0.1

3i Infrastructure PLC

332

320

0.5

-

-

Pantheon Infrastructure PLC

285

312

0.4

0.1

0.2

International Public Partnerships Limited

259

300

0.4

-

-

JLEN Environmental Assets Group Limited

232

320

0.3

-

0.1

Total infrastructure investment trusts

1,444

1,624

2.1

 

 

 

Open-ended investment companies7

 

 

 

 

 

Royal London Short Term Fixed Income Fund (Class Y Income)

1,024

1,020

1.5

0.1

0.2

Royal London Short Term Money Market Fund (Class Y Income)

1,004

1,026

1.5

-

-

Total open-ended investment companies

2,028

2,046

3.0

 

 

 

Money market funds7

 

 

 

 

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

1,000

1,000

1.5

-

-

Aviva Investors Sterling Government Liquidity Fund

1,000

1,000

1.5

-

0.1

BlackRock Institutional Sterling Government Liquidity Fund (Core Dis)

1,000

1,000

1.5

-

0.1

Fidelity Institutional Liquidity Sterling Fund (Class F)

1,000

1,000

1.5

0.1

0.2

HSBC Sterling Liquidity Fund (Class A)

1,000

1,000

1.4

-

-

Total money market funds

5,000

5,000

7.4

 

 

 

 

 

 

 

 

Total investments

61,587

62,247

90.8

 

 

 

1 Other clients of Maven Capital Partners UK LLP.

2 This holding reflects the retained minority interest following the sale of e.fundamentals (Group) Limited to CommerceIQ in July 2022.

3 Retained minority interest following the sale of Quorum Cyber Security Limited in December 2021.

4 This company delisted from AIM during a previous period.

5 Investments are quoted on AIM/AQSE with the exception of Kanabo Group PLC, which is listed on the Main Market of the London Stock Exchange.

6 The holding in this investment resulted from the sale of The GP Service (UK) Limited, which completed in February 2022. The unlisted shares in Kanabo GP Limited were, in accordance with the terms of the original transaction, exchanged for shares in Kanabo Group PLC, which is listed on the Main Market of the London Stock Exchange.

7 Treasury management portfolio.

 

Shaded line indicates that the investment was completed pre November 2015.

 

 

Income Statement

 

For the Six Months Ended 31 May 2024

 

 

Six months ended

31 May 2024 (unaudited)

Six months ended

31 May 2023 (unaudited)

Year ended

30 November 2023 (audited)

 

Revenue

£'000

Capital

£'000

Total

 £'000

Revenue

£'000

Capital

£'000

Total £'000

Revenue

£'000

Capital

£'000

Total

 £'000

Gain/(loss) on investments

-

1,577

1,577

-

(958)

(958)

-

(2,419)

(2,419)

Income from investments

481

-

481

234

-

234

736

-

736

Other income

83

-

83

132

-

132

187

-

187

Investment management fees

(141)

(425)

(566)

(141)

(424)

(565)

(284)

(851)

(1,135)

Other expenses

(207)

 

(207)

(246)

-

(246)

(460)

(4)

(464)

Net return on ordinary activities before taxation

216

1,152

1,368

(21)

(1,382)

(1,403)

179

(3,274)

(3,095)

Tax on ordinary activities

-

-

-

-

-

-

-

-

-

Return attributable to Equity Shareholders

216

1,152

1,368

(21)

(1,382)

(1,403)

179

(3,274)

(3,095)

 

Earnings per share (pence)

 

0.11

 

0.57

 

0.68

 

(0.01)

 

(0.75)

 

(0.76)

 

0.09

 

(1.72)

 

(1.63)

 

All gains and losses are recognised in the Income Statement.

 

The total column of this statement is the Profit & Loss Account of the Company. The revenue and capital return columns are prepared in accordance with the AIC SORP. All items in the above statement derive from continuing operations. No operations were acquired or discontinued during the period.

 

There are no potentially dilutive capital instruments in issue and, therefore, no diluted earnings per share figures are relevant. The basic and diluted earnings per share are, therefore, identical.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Statement Of Changes In Equity

 

Six Months Ended 31 May 2024

 

Six months ended 31 May 2024 (unaudited)

 

Non-distributable reserves

Distributable reserves

 

 

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve unrealised

£'000

Capital reserve

realised

£'000

Special distributable

reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2023

19,539

20,068

825

(874)

8,800

16,757

(1,555)

Net return

-

-

-

1,764

(187)

(425)

216

1,368

Dividends paid

-

-

-

-

-

(2,119)

(101)

(2,220)

Repurchase and cancellation of shares

(566)

-

566

-

-

(1,729)

-

(1,729)

Net proceeds of share issue

2,095

4,540

-

-

-

-

-

6,635

Net proceeds of DIS issue*

71

153

-

-

-

-

-

224

At 31 May 2024

21,139

24,761

1,391

890

8,613

12,484

(1,440)

67,838

 

 

Six months ended 31 May 2023 (unaudited)

 

Non-distributable reserves

Distributable reserves

 

 

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve

unrealised £'000

Capital reserve

realised

£'000

Special distributable

reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2022

17,638

15,063

691

404

9,941

20,448

(1,734)

62,451

Net return

-

-

-

(1,181)

223

(424)

(21)

(1,403)

Dividends paid

-

-

-

-

-

(934)

-

(934)

Repurchase and cancellation of shares

(72)

-

72

-

-

(240)

-

(240)

Net proceeds of share issue

1,714

4,321

-

-

-

-

-

6,035

Net proceeds of DIS issue*

29

73

-

-

-

-

-

102

At 31 May 2023

19,309

19,457

763

(777)

10,164

18,850

(1,755)

66,011

 

 

Year ended 30 November 2023 (audited)

 

Non-distributable reserves

Distributable reserves

 

 

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve

unrealised £'000

Capital reserve

realised

£'000

Special distributable

reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2022

17,638

15,063

691

404

9,941

20,448

(1,734)

62,451

Net return

-

-

-

(1,278)

(1,141)

(855)

179

(3,095)

Dividends paid

-

-

-

-

-

(2,400)

-

(2,400)

Repurchase and cancellation of shares

(134)

-

134

-

-

(436)

-

(436)

Net proceeds of share issue

1,957

4,819

-

-

-

-

-

6,776

Net proceeds of DIS issue*

78

186

-

-

-

-

-

264

At 30 November 2023

19,539

20,068

825

(874)

8,800

16,757

(1,555)

63,560

 

*DIS represents the Dividend Investment Scheme as detailed in the Interim Review.

 

The capital reserve unrealised is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments which are distributable.

 

Where all, or an element of the proceeds of sales have not been received in cash or cash equivalent, and are not readily convertible to cash, they do not qualify as realised gains for the purposes of distributable reserves calculations and, therefore, do not form part of distributable reserves.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Balance Sheet

 

As At 31 May 2024

 

 

31 May 2024

(unaudited)

£'000

31 May 2023

(unaudited)

£'000

30 November 2023

(audited)

£'000

Fixed assets

 

 

 

Investments at fair value through profit or loss

61,587

58,967

59,736

 

Current assets

 

 

 

Debtors

699

615

633

Cash

5,856

6,657

3,492

 

6,555

7,272

4,125

Creditors

 

 

 

Amounts falling due within one year

(304)

(228)

(301)

Net current assets

6,251

7,044

3,824

Net assets

67,838

66,011

63,560

 

Capital and reserves

 

 

 

Called up share capital

21,139

19,309

19,539

Share premium account

24,761

19,457

20,068

Capital redemption reserve

1,391

763

825

Capital reserve - unrealised

890

(777)

(874)

Capital reserve - realised

8,613

10,164

8,800

Special distributable reserve

12,484

18,850

16,757

Revenue reserve

(1,440)

(1,755)

(1,555)

Net assets attributable to Ordinary Shareholders

67,838

66,011

63,560

Net asset value per Ordinary Share (pence)

32.09

34.18

32.53

 

The Financial Statements of Maven Income and Growth VCT 5 PLC, registered number 04084875, were approved and authorised for issue by the Board of Directors and were signed on its behalf by:

 

 

Graham Miller

Director

 

12 July 2024

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Cash Flow Statement

 

For the Six Months Ended 31 May 2024

 

 

Six months ended 31 May 2024

(unaudited)

£'000

Six months ended 31 May 2023

(unaudited)

£'000

Year ended

30 November 2023

(audited)

£'000

Net cash flows from operating activities

 

(271)

(822)

(1,136)

Cash flows from investing activities

 

 

 

Purchase of investments

(5,967)

(17,446)

(24,207)

Sale of investments

5,692

659

5,220

Net cash flows from investing activities

(275)

(16,787)

(18,987)

 

Cash flows from financing activities

 

 

 

Equity dividends paid

(2,220)

(934)

(2,400)

Issue of Ordinary Shares

6,859

6,137

7,148

Repurchase of Ordinary Shares

(1,729)

(240)

(436)

Net cash flows from financing activities

2,910

4,963

4,312

 

 

 

 

Net increase/(decrease) in cash

2,364

(12,646)

(15,811)

 

Cash at beginning of period

 

3,492

 

19,303

 

19,303

Cash at end of period

5,856

6,657

3,492

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Notes to the Financial Statements

 

1.  Accounting policies

 

The financial information for the six months ended 31 May 2024 and the six months ended 31 May 2023 comprises non-statutory accounts within the meaning of s435 of the Companies Act 2006. The financial information contained in this report has been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 30 November 2023, which have been filed at Companies House and contained an Auditor's Report that was not qualified and did not contain a statement under s498 (2) or s498 (3) of the Companies Act 2006.

 

2.   Reserves

 

Share premium account

 

The share premium account represents the premium above nominal value received by the Company on issuing shares net of issue costs, including £61,395 current period (£169,359 cumulative) trail commission. This reserve is non-distributable.

 

Capital redemption reserve

 

The nominal value of shares repurchased and cancelled is represented in the capital redemption reserve. This reserve is non-distributable.

 

Capital reserve - unrealised

 

Increases and decreases in the fair value of investments are recognised in the Income Statement and are then transferred to the capital reserve unrealised account. This reserve is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments which are distributable.

 

Capital reserve - realised

 

Gains or losses on investments realised in the period that have been recognised in the Income Statement are transferred to the capital reserve realised account on disposal. Furthermore, any prior unrealised gains or losses on such investments are transferred from the capital reserve unrealised account to the capital reserve realised account on disposal. This reserve is distributable.

 

Special distributable reserve

 

The total cost to the Company of the repurchase and cancellation of shares is represented in the special distributable reserve account. The special distributable reserve also represents capital dividends, capital investment management fees and the tax effect of capital items. This reserve is distributable.

 

Revenue reserve

 

The revenue reserve represents accumulated profits retained by the Company that have not been distributed to Shareholders as a dividend. This reserve is distributable.

 

3.   Return per Ordinary Share

 

 

Six months ended 31 May 2024

The returns per share have been based on the following figures:

 

Weighted average number of Ordinary Shares

 

Revenue return

Capital return

 

 

202,443,505

 

£216,000

£1,152,000

Total return

£1,368,000

 

 

Directors' Responsibility Statement

 

The Directors confirm that, to the best of their knowledge:

 

•    the Financial Statements for the six months ended 31 May 2024 have been prepared in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland;

 

•    the Interim Management Report includes a fair review of the information required by DTR 4.2.7R in relation to the indication of important events during the first six months, and of the principal and emerging risks and uncertainties facing the Company during the second six months, of the year ending 30 November 2024; and

 

•    the Interim Management Report includes adequate disclosure of the information required by DTR 4.2.8R in relation to related party transactions and any changes therein.

 

Other information

 

The NAV per Ordinary Share has been calculated using the number of Ordinary Shares in issue at 31 May 2024, which was 211,399,652. A summary of investment changes for the six months under review and an investment portfolio summary as at 31 May 2024 are included above. A full copy of the Interim Report and Financial Statements will be printed and issued to Shareholders in due course. Copies of this announcement will be available to the public at the office of Maven Capital Partners UK LLP, Kintyre House, 205 West George Street, Glasgow, G2 2LW; at the registered office of the Company at 6th Floor, Saddlers House, 44 Gutter Lane, London EC2V 6BR; and on the Company's website at: mavencp.com/migvct5.

 

Neither the content of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

 

By order of the Board

Maven Capital Partners UK LLP

Secretary

 

12 July 2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR SFIFIEELSESW